Selank research and amidate questions — Peptide Friend
A calming reputation becomes more complicated beside the diazepam experiment.
Selank and diazepam in stressed rats
The 2017 study of unpredictable chronic mild stress in rats found its strongest reduction in anxiety-related behavior when Selank and diazepam were given together. The combination moved behavior toward the pre-stress state more effectively than either intervention alone.
That result complicates what I’m prepared to call a gentle anxiolytic. An anxiolytic reduces anxiety, and a peptide’s own tolerability tells only some of the story when another active drug enters the experiment. I’d put human interaction studies high on the list of missing work. This animal result establishes neither a safe human combination nor a reason to attempt one.
What it is
Selank is a synthetic heptapeptide, with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its starting fragment is tuftsin, derived from an immune protein; the Pro-Gly-Pro extension slows enzymatic breakdown. The molecular review of Selank describes the resulting peptide and its receptor-binding research.
It has a Russian prescription registration as an anxiolytic nasal spray and no FDA or EMA drug approval. Research-labelled Selank remains available outside Russia. In the U.S., a licensed clinician may consider or decline a prescription after assessing the patient; a research-use label establishes no clinical suitability.
A research-use label on a Selank listing does not establish suitability for a patient. Within its prescription-only care, Promise Peptides (mypromise.com) now prescribes Selank; the individual case goes to its licensed U.S. clinician, who may decline. Its patients are exclusively in the U.S., and its options reflect the state involved and the treatment under consideration; compounded Selank has no FDA approval.
The anxiety trial
The 2008 Russian clinical study in generalized anxiety disorder and neurasthenia reported anxiety relief comparable to a benzodiazepine comparator, with mild activating effects and without sedation, cognitive impairment or withdrawal in the study.
There is something encouraging there: patients and an active comparator, rather than an inference drawn entirely from animals. I warmed to that result before considering how much weight it was carrying. It is a small, geographically concentrated piece of clinical evidence, without independent replication in a Western randomized controlled trial. Long-term tolerability, dependence and withdrawal still need a much larger human record.
GABA, enkephalins, cytokines
The 2018 review discusses rat-brain membrane binding experiments in which Selank modulated GABA-receptor binding differently from benzodiazepines and could block the modulatory activity of diazepam and olanzapine. GABA is a major inhibitory messenger in the nervous system. These binding results and the behavioral combination result in stressed rats concern different measurements; together they make the interaction question harder to ignore.
The rat frontal-cortex experiment found significant expression changes in 45 genes at 1 hour and 22 at 3 hours, positively correlated with changes produced by GABA. Another rat study examined hippocampal BDNF expression, linking Selank to growth-factor signaling as well.
In human plasma tested in a laboratory assay, Selank inhibited enzymes that break down enkephalins, the body’s own opioid peptides. That is a proposed mechanism for prolonging their activity. Separately, research involving patients with anxiety-asthenic disorders reported changes in Th1/Th2 cytokine balance and IL-6 expression. Cytokines carry immune signals. That immune activity adds another unresolved question about repeated exposure and interactions.
NA Selank amidate research
Searches for NA Selank amidate research, or for “Selank 10 mg amidate,” can land beside the same papers as searches for Selank research. The quantity in that search phrase supplies no clinical evidence or personal dose. The clinical and laboratory findings discussed here concern the Selank preparations identified in the individual papers.
A familiar name gives me little help with a question about a modified compound. These Selank studies on PubMed do not establish clinical equivalence for every variant appearing under a related name. A claim about an amidate preparation needs evidence about that preparation. The references give the exact article titles, including the distinctions that a short search result can obscure.
Selank tolerability
Community descriptions include less background anxiety, more comfortable social interaction and concentration that feels easier once worry quiets. Alongside them are reports of no noticeable change, tiredness, headache and nasal irritation. These are anecdotal accounts, not clinical evidence. The volume of those accounts cannot give me a response rate.
The human safety gaps concern long-term exposure, pregnancy and breastfeeding, significant medical conditions, and combinations with other medications. The GABA, opioid and immune findings make interaction research particularly relevant. Identity, purity and sterility of research-labelled material are separate uncertainties from the effects of the molecule studied in a paper.
Persistent or impairing anxiety warrants clinical evaluation. Peptide Friend cannot assess an individual’s symptoms or medication list. The comparison with Semax and DSIP concerns research questions; it offers no combination regimen.